An observational study in Acute Ovarian Failure, Infertility and Early Menopause And Infertility In Females After Treatment For Childhood Cancer, sponsored by Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD). Completed at 1 site in United States. Open to female participants aged 4 Years to 35 Years. Per ClinicalTrials.gov, last updated 2026-11-03.
Sponsored by Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 13 studies in Infertility by Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) — 1 open to participants now, 1 under way, none of them phase 3. Infertility · Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD).
Among the 13 studies in Infertility by Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), this one is the only one that started in 2022, is one of 9 observational ones, and was the 12th registered.
2,088 studies on the registry are indexed under Infertility; 356 are open to participants now.
Browse Infertility studies →1 of the 13 studies in Infertility by Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) is open now, in 1 country. Recruiting first, the newest first:
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) · Sites in United States
Ages 18–100
By country, each count listing its studies:
Of the 234 Infertility studies recruiting now, 43 (18%) set no upper age limit and 185 (79%) stop at 75 or younger; 27 take children under 18; 76 take healthy volunteers.
This study: 4 Years to 35 Years · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
13 studies; the count open now beside each. This study's row is marked.
First in 1991; this study’s year is marked. 1 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 16 is below the median of 200 across 591 observational studies indexed under Infertility.
Median enrollment 591 across the 4 interventional studies, 266 across the 9 observational. Of the 11 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) is the lead sponsor of 422 studies on the registry; 24 are open to participants now.
Of its 14 completed or terminated interventional studies of FDA-regulated products, 11 (79%) have results posted.
None of the studies under way reaches primary completion within a year.
Among the 13 studies in Infertility by Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), from their registry updates:
This tab as a report to print or save as PDF → With an account.
Background:
Medical advances have improved survival rates for many cancers and other illnesses. This means that more people are coping with the long-term effects of these treatments. Some treatments can cause female infertility. Ovarian tissue cryopreservation (OTC) may help. Before undergoing a treatment that may damage their fertility, patients may opt to freeze a sample of ovarian tissue. The tissue contains immature egg cells. When thawed, the tissue can be reimplanted. This procedure can help women become pregnant.
Objective:
This natural history study will create a databank of ovarian tissue. The NIH will provide OTC as a clinical service. The NIH will also request a portion of the tissue to use for research.
Eligibility:
Females aged 4 to 35 who opt to have OTC before receiving cancer treatment.
Design:
Participants will be screened. Their existing medical records will be reviewed.
They will be asked if they want to donate a portion of their ovarian tissue for research. No more than 20% of the tissue collected will be taken for research. Some other tissues that would otherwise be discarded will also be kept.
Medical data from each participant may also be collected and stored in the database. This data may include results of routine blood tests, imaging tests, and other information. The data will be coded for privacy.
Participants will answer a questionnaire. They will be asked about their fertility treatment and general health. The survey takes about 30 minutes.
They will repeat the questionnaire once a year for 30 years.
Study Description:
We will provide ovarian tissue cryopreservation (OTC) as a clinical service at NIH and collect a portion of the tissue for research regarding normal histology and function of the human ovary. In addition, de-identified data will be entered in a national database which will allow future research regarding short term and long term complications (Including impact of therapy on remaining ovarian function), as well as long term outcomes including reproductive health outcomes (including rate of tissue reimplantation and pregnancies)
Objectives:
Primary objective: is to create a databank of human ovarian tissue to elucidate histology and function in human ovaries.
Secondary objective: will be to populate a national database of individuals who have undergone OTC in order to elucidate short and long term outcomes including complications and reproductive health parameters.
Subjects who will undergo gonadotoxic treatment at NCI.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
In order to be eligible to participate in this study, an individual must meet all of the following criteria:
EXCLUSION CRITERIA:
-An individual who meets any of the following criteria will be excluded from participation in this study:
--Adults subjects with psychological, psychiatric, or other conditions which prevent giving fully .
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Subjects who have planned to undergo OTC for gonadotoxic therapy based on current standard of care.
create a databank of human ovarian tissue
Create a databank of human ovarian tissue to elucidate histology and function in human ovaries
Time frame: end of study
create a databank of human ovarian tissue to elucidate histology and function in human ovaries
Populate a national database of individuals who have undergone OTC in order to elucidate short and long term outcomes including complications and reproductive health parameters.
Time frame: end of study
Plan to share: Undecided
Ran from Jul 2022 to primary completion in Oct 2026, 50 months.
Of 209 non-industry observational studies under Infertility, half reached primary completion within 39 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 100. This study's 50 months is above that.
Counting every sponsor, half of 240 studies reached it within 39 months; a quarter within 16 and three quarters within 99.
Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 3, 2026: primary completion Sep 2041 → Oct 2026 and completion Sep 2041 → Oct 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to trackQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) →